Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Glaucoma > Early results show viscoelastic delivery device lowers IOP in eyes with POAG undergoing cataract surgery
  • Glaucoma

Early results show viscoelastic delivery device lowers IOP in eyes with POAG undergoing cataract surgery

Ophthalmology 360

Significant IOP and medication reductions were noted in eyes with mild to moderate glaucoma after goniotomy performed with Streamline Surgical System (New World Medical), according to early data from an interim analysis presented at ASCRS 2022. According to the presentation, the safety profile was similar to other minimally invasive glaucoma surgical interventions.

In this interim analysis, 21 eyes had a 37.4% reduction in IOP, starting with a washout baseline of 23.9 (±5.4) and reducing to 14.9 (±5.1) mmHg at month 9 (P < 0.001). In addition, medications were reduced at month 9 to 1.1 from 2.1 at screening. At 9 months, most eyes (95.2%) ≥20% reduction from baseline IOP and no increase in medication use. There were no reported adverse events related to the procedure.

Streamline received 510k clearance from the FDA in late 2021.

Reference
Yeu E, et al. Interim Results of a Novel Dual-Port Microcatheter Used to Delivery Viscoelastic in Eyes with Primary Open-Angle Glaucoma (POAG). Presented at: ASCRS 2022.

Share

Related Content

  • Glaucoma

Study finds significant IOP reductions with iDose TR and MIGS procedures

  • Glaucoma

EyeValve device lowers IOP and maintains control for 9 months in first-in-human study

  • Glaucoma

GLP-1 therapies may offer potential benefits in glaucoma

  • Glaucoma

PreserFlo MicroShunt shows short-term benefit in refractory childhood glaucoma

  • Glaucoma

iStent adoption rises as surgeons treat glaucoma earlier

  • Glaucoma

Review finds low adverse event rates for glaucoma stents

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon